Poniard Pharmaceuticals, Inc. Announces Executive Terminations
Apr 2 12
On March 30, 2012, due to its current financial condition Poniard Pharmaceuticals, Inc. terminates Michael S. Perry, DVM, PhD, its President, Chief Operating Officer and Chief Medical Officer, and Michael K. Jackson, its Interim Chief Financial Officer and Chief Accounting Officer, effective March 31, 2012. Perry and Mr. Jackson will become consultants to the company under consulting arrangements yet to be completed. Perry will receive severance benefits under his amended and restated Key Executive Severance Agreement dated as of February 5, 2010. Jackson will receive severance benefits under his amended and restated Key Executive Severance Agreement dated as of February 24, 2009.
Poniard Pharmaceuticals Files Form 15
Apr 2 12
Poniard Pharmaceuticals, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock of par value of $0.02 per share under the Securities Exchange Act of 1934, as amended.
Poniard Pharmaceuticals, Inc. announced delayed annual 10-K filing
Mar 30 12
On 03/30/2012, Poniard Pharmaceuticals, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.